Immunopathology of Leishmaniasis: An Update

Leishmaniasis represents a severe, increasing, public health problem. The perspective of its control is highly dependent on research progress, on therapeutic manipulations of the immune system, and on vaccine development. There is a correlation between the clinical outcome of Leishmania infection and the cytokine response profile. While a protective immune response against Leishmania has been clearly identified to be related to the influence of a type-1 response and IFN-γ production, the precise role of T helper (TH) 2 cytokines in non-healing infections requires further exploration. IL-4 and IL-13 (TH2 cytokines) can promote disease progression in cutaneous leishmaniasis, whereas IL-4 would appear to enhance protective type-1 responses in visceral leishmaniasis. Thus, the TH1/TH2 paradigm of resistance/susceptibility to intracellular parasites is probably an oversimplification of a more complicated network of regulatory/counter regulatory interactions. Moreover, the presence of antigen specific regulatory T cell subsets may provide an environment that contributes to the balance between TH1 and TH2 cells. Finally, the involvement of CD8+ T cells has been described, but the modality of their function in this kind of infection has not been so far elucidated.

[1]  P. Kaye,et al.  CD95 is required for the early control of parasite burden in the liver of Leishmania donovani‐infected mice , 2001, European journal of immunology.

[2]  F. Miedema,et al.  T cell subset and cytokine profiles in human visceral leishmaniasis during active and asymptomatic or sub-clinical infection with Leishmania donovani. , 2005, Clinical immunology.

[3]  C. Mackay,et al.  T cell effector subsets: extending the Th1/Th2 paradigm. , 2001, Advances in immunology.

[4]  J. Blackwell,et al.  Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis. , 1991, Journal of immunology.

[5]  R. Soliman,et al.  Enhancement of leishmanicidal activity of human macrophages against Leishmania major and Leishmania donovani infection using recombinant human granulocyte macrophage colony stimulating factor. , 1996, Zentralblatt fur Bakteriologie : international journal of medical microbiology.

[6]  C. Bern,et al.  The epidemiology of visceral leishmaniasis in Bangladesh: prospects for improved control. , 2006, The Indian journal of medical research.

[7]  M. Gramiccia,et al.  The current status of zoonotic leishmaniases and approaches to disease control. , 2005, International journal for parasitology.

[8]  B. Davidson,et al.  The importance of TGF-beta in murine visceral leishmaniasis. , 1998, Journal of immunology.

[9]  W. de Souza,et al.  Expression and processing of megasome cysteine proteinases during Leishmania amazonensis differentiation , 2002, Parasitology Research.

[10]  T. Theander,et al.  Immunopathology of post kala‐azar dermal leishmaniasis (PKDL): T‐cell phenotypes and cytokine profile , 1999, The Journal of pathology.

[11]  C. Hunter,et al.  Cutting Edge: Early IL-4 Production Governs the Requirement for IL-27-WSX-1 Signaling in the Development of Protective Th1 Cytokine Responses following Leishmania major Infection1 , 2004, The Journal of Immunology.

[12]  P. Tsagozis,et al.  Function of CD8+ T lymphocytes in a self-curing mouse model of visceral leishmaniasis. , 2005, Parasitology international.

[13]  C. Barbiéri.  Immunology of canine leishmaniasis , 2006, Parasite immunology.

[14]  J. Louis,et al.  The murine model of infection with Leishmania major and its importance for the deciphering of mechanisms underlying differences in Th cell differentiation in mice from different genetic backgrounds. , 2004, International journal for parasitology.

[15]  G. Das,et al.  Leishmania donovani Infection of a Susceptible Host Results in CD4+ T‐Cell Apoptosis and Decreased Th1 Cytokine Production , 1999, Scandinavian journal of immunology.

[16]  A. Khamesipour,et al.  The contribution of the Fas/FasL apoptotic pathway in ulcer formation during Leishmania major-induced cutaneous Leishmaniasis. , 2005, The American journal of pathology.

[17]  S. Reed,et al.  Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis. , 1994, Journal of immunology.

[18]  S. Coutinho,et al.  Detection of early apoptosis and cell death in T CD4+ and CD8+ cells from lesions of patients with localized cutaneous leishmaniasis. , 2000, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[19]  G. H. Coombs,et al.  Inhibition of Lipopolysaccharide-Induced Macrophage IL-12 Production by Leishmania mexicana Amastigotes: The Role of Cysteine Peptidases and the NF-κB Signaling Pathway1 , 2004, The Journal of Immunology.

[20]  J. Renauld,et al.  Cytokine Production and Killer Activity of NK/T-NK Cells Derived with IL-2, IL-15, or the Combination of IL-12 and IL-181 , 2000, The Journal of Immunology.

[21]  J. Tschopp,et al.  The resolution of lesions induced by Leishmania major in mice requires a functional Fas (APO‐1, CD 95) pathway of cytotoxicity , 1998, European journal of immunology.

[22]  E. Cillari,et al.  The significance of serum soluble IL‐2 receptor as a marker for active visceral leishmaniasis in Sicilian patients , 1992, Clinical and experimental immunology.

[23]  S. Brooker,et al.  Recent advances in research and control of malaria, leishmaniasis, trypanosomiasis and schistosomiasis. , 2003, Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit.

[24]  C. Hunter,et al.  Anti-TGF-beta treatment promotes rapid healing of Leishmania major infection in mice by enhancing in vivo nitric oxide production. , 1999, Journal of immunology.

[25]  C. Hallahan,et al.  CD4 T cell expansions are associated with increased apoptosis rates of T lymphocytes during IL-2 cycles in HIV infected patients , 2001, AIDS.

[26]  F. Liew,et al.  Suppression of IL-2 production by cryopreserved peripheral blood mononuclear cells from patients with active visceral leishmaniasis in Sicily. , 1988, Journal of immunology.

[27]  R. Steffen,et al.  Health problems after travel to developing countries. , 1987, The Journal of infectious diseases.

[28]  F. Liew,et al.  Cytokines and nitric oxide as effector molecules against parasitic infections. , 1997, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[29]  J. Webb,et al.  IL-12Rbeta2-deficient mice of a genetically resistant background are susceptible to Leishmania major infection and develop a parasite-specific Th2 immune response. , 2003, Microbes and infection.

[30]  M. Lohmann‐Matthes,et al.  The capacity to produce IFN-gamma rather than the presence of interleukin-4 determines the resistance and the degree of susceptibility to Leishmania donovani infection in mice. , 2000, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[31]  U. Ritter,et al.  Monocyte chemotactic protein‐1 stimulates the killing of Leishmania major by human monocytes, acts synergistically with IFN‐γ  and is antagonized by IL‐4 , 2000, European journal of immunology.

[32]  J. Blackwell,et al.  IL-13 Is a Susceptibility Factor for Leishmania major Infection , 2000, The Journal of Immunology.

[33]  T. Waldmann,et al.  The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. , 1999, Annual review of immunology.

[34]  F. Liew,et al.  Immunology of murine leishmaniasis. , 1996, Clinics in dermatology.

[35]  A. Kariminia,et al.  Transforming Growth Factor β1 Production by CD4+ CD25+ Regulatory T Cells in Peripheral Blood Mononuclear Cells from Healthy Subjects Stimulated with Leishmania guyanensis , 2005, Infection and Immunity.

[36]  W. Paul,et al.  The Relative Contribution of IL-4 Receptor Signaling and IL-10 to Susceptibility to Leishmania major1 , 2003, The Journal of Immunology.

[37]  Y. Carlier,et al.  Immunological factors governing resistance and susceptibility of mice to Leishmania major infection. , 2001, Revista latinoamericana de microbiologia.

[38]  J. Farrell,et al.  CD 40-CD 40 Ligand Costimulation Is Not Required for Initiation and Maintenance of a Th 1-Type Response to Leishmania major Infection , 2003 .

[39]  H. Moll,et al.  Leishmania major Modulates Chemokine and Chemokine Receptor Expression by Dendritic Cells and Affects Their Migratory Capacity , 2005, Infection and Immunity.

[40]  T. Idziorek,et al.  T helper type 1/T helper type 2 cytokines and T cell death: preventive effect of interleukin 12 on activation-induced and CD95 (FAS/APO-1)- mediated apoptosis of CD4+ T cells from human immunodeficiency virus- infected persons , 1995, The Journal of experimental medicine.

[41]  D. Sacks,et al.  The immunology of susceptibility and resistance to Leishmania major in mice , 2002, Nature Reviews Immunology.

[42]  F. Pratlong,et al.  Phylogenetic taxonomy of New World Leishmania. , 1993, Annales de parasitologie humaine et comparee.

[43]  J. Berman,et al.  Advances in leishmaniasis , 2005, The Lancet.

[44]  T. Theander,et al.  Leishmania donovani-reactive Th1- and Th2-like T-cell clones from individuals who have recovered from visceral leishmaniasis , 1993, Infection and immunity.

[45]  Y. Belkaid.  The role of CD4+CD25+ regulatory T cells in Leishmania infection , 2003, Expert opinion on biological therapy.

[46]  E. Cillari,et al.  Interleukin‐15, as Interferon‐gamma, Induces the Killing of Leishmania infantum in Phorbol‐Myristate‐Acetate‐Activated Macrophages Increasing Interleukin‐12 , 2004, Scandinavian journal of immunology.

[47]  R. Haque,et al.  Multiplex analysis of circulating cytokines in the sera of patients with different clinical forms of visceral leishmaniasis , 2006, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[48]  P. Holzmuller,et al.  Phenotypical characteristics, biochemical pathways, molecular targets and putative role of nitric oxide-mediated programmed cell death in Leishmania , 2006, Parasitology.

[49]  Xiaojing Ma,et al.  Responses to Leishmania donovani in Mice Deficient in Interleukin-12 (IL-12), IL-12/IL-23, or IL-18 , 2006, Infection and Immunity.

[50]  T. Theander,et al.  The contrasting roles of CD4+ T cells in intracellular infections in humans: leishmaniasis as an example. , 1996, Immunology today.

[51]  S. Kar,et al.  Demonstration of Leishmania parasites in skin lesions of Indian post kala-azar dermal leishmaniasis (PKDL) cases. , 2000, The Journal of communicable diseases.

[52]  G. Trinchieri,et al.  The role of IL‐12 in the maintenance of an established Th1 immune response in experimental leishmaniasis , 1998, European journal of immunology.

[53]  D. Dockrell.  Apoptotic cell death in the pathogenesis of infectious diseases. , 2001, The Journal of infection.

[54]  J. Farrell,et al.  CD40-CD40 Ligand Costimulation Is Not Required for Initiation and Maintenance of a Th1-Type Response to Leishmania major Infection , 2003, Infection and Immunity.

[55]  P. Scott,et al.  Expression and contribution of B7-1 (CD80) and B7-2 (CD86) in the early immune response to Leishmania major infection. , 1999, Journal of immunology.

[56]  Mohamed,et al.  Interleukin 10 production correlates with pathology in human Leishmania donovani infections. , 1993, The Journal of clinical investigation.

[57]  P. Tsagozis,et al.  CD8+ T cells with parasite‐specific cytotoxic activity and a Tc1 profile of cytokine and chemokine secretion develop in experimental visceral leishmaniasis , 2003, Parasite immunology.

[58]  K. Gollob,et al.  Insights into CD4+ memory T cells following Leishmania infection. , 2005, Trends in parasitology.

[59]  S. Reed,et al.  Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. , 1985, The Journal of clinical investigation.

[60]  J. Streit,et al.  Visceral Leishmaniasis , 2011 .

[61]  G. H. Coombs,et al.  Expression of Multiple CPB Genes Encoding Cysteine Proteases Is Required for Leishmania mexicana Virulence In Vivo , 2003, Infection and Immunity.

[62]  G. Stassi,et al.  In vivo and in vitro cytokine profiles and mononuclear cell subsets in Sicilian patients with active visceral leishmaniasis. , 1995, Cytokine.

[63]  E. Cillari,et al.  IL‐15 in human visceral leishmaniasis caused by Leishmania infantum , 2002, Clinical and experimental immunology.

[64]  M. T. Roberts.  Current understandings on the immunology of leishmaniasis and recent developments in prevention and treatment. , 2005, British medical bulletin.

[65]  R. Titus,et al.  The influence of antigen-presenting cell type and interferon-gamma on priming and cytokine secretion of Leishmania major-specific T cells. , 1997, The Journal of infectious diseases.

[66]  A. Satoskar,et al.  Disruption of the murine interleukin-4 gene inhibits disease progression during Leishmania mexicana infection but does not increase control of Leishmania donovani infection , 1995, Infection and immunity.

[67]  S. Romagnani,et al.  The Th1/Th2 paradigm. , 1997, Immunology today.

[68]  J. Alexander,et al.  T helper (h)1/Th2 and Leishmania: paradox rather than paradigm. , 2005, Immunology letters.

[69]  L. Azzoni,et al.  Expression of type 1 (interferon gamma) and type 2 (interleukin-13, interleukin-5) cytokines at distinct stages of natural killer cell differentiation from progenitor cells. , 2002, Blood.

[70]  F. Dantas-Torres,et al.  Visceral leishmaniasis in Brazil: revisiting paradigms of epidemiology and control. , 2006, Revista do Instituto de Medicina Tropical de Sao Paulo.

[71]  M. Rogers,et al.  New insights into the developmental biology and transmission mechanisms of Leishmania. , 2004, Current molecular medicine.

[72]  W. de Souza,et al.  Cell biology of Leishmania spp.: invading and evading. , 2002, Current pharmaceutical design.

[73]  P. Kaye,et al.  Both Interleukin-4 (IL-4) and IL-4 Receptor α Signaling Contribute to the Development of Hepatic Granulomas with Optimal Antileishmanial Activity , 2003, Infection and Immunity.

[74]  P. Salotra,et al.  Elevated levels of interferon-gamma, interleukin-10, and interleukin-6 during active disease in Indian kala azar. , 2006, Clinical immunology.

[75]  K. Flanders,et al.  Antagonizing Deactivating Cytokines To Enhance Host Defense and Chemotherapy in Experimental Visceral Leishmaniasis , 2005, Infection and Immunity.

[76]  F. Liew,et al.  Reduction in the number of UCHL-1+ cells and IL-2 production in the peripheral blood of patients with visceral leishmaniasis. , 1991, Journal of immunology.

[77]  G. Trinchieri,et al.  IL-12 enhances Th1-type responses in human Leishmania donovani infections. , 1995, Journal of immunology.

[78]  S. Kar,et al.  Mechanisms of pathogenesis: differences amongst Leishmania species. , 2002, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[79]  G. Romano,et al.  CD4+ CCR5+ and CD4+ CCR3+ lymphocyte subset and monocyte apoptosis in patients with acute visceral leishmaniasis , 2004, Immunology.

[80]  S. Jeronimo,et al.  IL-10 and IL-12 are the main regulatory cytokines in visceral leishmaniasis. , 2000, Cytokine.

[81]  M. Nunes,et al.  CD40 signaling induces reciprocal outcomes in Leishmania-infected macrophages; roles of host genotype and cytokine milieu. , 2005, Microbes and infection.